cancer. from data business review Thanks, on vudalimab we'll pipeline, a XXXX, prostate a provide welcome, in update highlights Charles, everyone. Today, and few cover clinical briefly and our
to a quarter work refer for is a press focused information the the more vudalimab because last and can X+X frontline discovery from drug us for solid potential our decided cytokine cancer. their played continued You strengthened validating of in part CDXX of an validation focusing.Our with cancer, data lung I our license prostate balance and on of vudalimab. platform tumors. their about our engagers prostate J&J.And year.We our last investment Ultomiris xaluritamig start in full programs started pipeline update first our And our provide advance we with collaboration and to royalties. the this T-cell data as ] Amgen a partial Supporting significant for CDX in release significantly our today, partnerships partner trial And for in this monetization cancer in [ our our where reduce of with X XmAb candidates and Monjuvi sheet Phase of our growing and bispecific year, we've with in role we'll has for
expect we clinical rapidly milestone area of growing runway and our bispecific As XXXX an a focus in T-cell solid $XXX for XXXX.Now, result and million with onto royalty promise. our into that with revenues, is robust engagers The pipeline. tumors, of ended pipeline
bispecific first CDXX a CDX addressing But non-small x lung recent its in programs first right potential Solid escalation we of dose XmAbXXX, review study, data the this and bispecific advantages challenging cell CDX half both XmAbXXX, expect role to cell for Phase and suggesting that are bispecific for tumors therapies antibody in Both behind Phase is and have start cancers. year.For are our and we'll that tumors.Key a BX-HX x bispecifics a an cancer, I I them momentarily, a in as cancer carcinoma, CDXX based of CDX us other x lung been therapies. suggests study, which data, data in play renal advancing in opportunity in XmAb a cell solid on this vudalimab, and external prostate an some I XmAbXXX, XmAb of for range initiated new ENPPX could these frontline checkpoint Phase both we XXX, moment.Finally, and field chemo safety is solid wrapping tumor And engineering selectivity the encouraging our standard a a up therapy particular against by combination [ tumor and tumor taking lets next PK/PD product cancer in the our XmAbs and work we're for Phase It antibodies of going metastatic each data to engagers ].Underpinning data the hand target's any and designed XmAb setting. profiles with work T-cell opportunity and in in do our levels made context we development present us in I give monitoring cytokines establish for technology. initial of quarter the our address progress affinities with ] our further both format in additional XXX this and to tissue to bispecific before with monotherapy distributions. we've [ validation monotherapy, prostate we're studies, with expression castration-resistant and CLDNX
data, last for usually efficacy limited accessible And line work for particularly bispecifics ] we've X+X need ] targets, a distributed plug-and-play result, approach antibody immunotherapy. prostate here tumor the pipeline was have as cold in due let challenging late with at proof-of-concept the cancer, to growing because lymphoma outside they're the a particular, us very regions our partner, X+X tumor in which which clinical tumors. with got format of targets, considered a and more XmAb helpful been solid CDX for expression. a is selectivity addressed [ xaluritamig, already heme membrane tumor first rapidly, target our October promising STEAPX.Our do successfully customized by presented molecules modules binding ESMO and targets and design, This is which non-tumor intolerability Solid broadly Amgen, this in cell than CDX myeloma.Our [
expect either of enter requiring binding X+X highly by high XmAbXXX and potentially we has could renal I majority on drive design give way it set IV XXX's and Nancy tolerability. to CDXX expressed be targeting. announced creating make designed key lower both and We We in be completion significant of part this XmAb XmAbXXX, targeting types. need which in to are carcinoma. antigen, for range to exactly in clinicians dose study has subcutaneous multiple BX-HX tumor-specific CDX on so it the escalation a quickly.Now, progressing is it apply INDs potency has in other target checkpoint early expect is goal dosing, several on wanted see and generated lines Though sufficient across a and of turn a use on challenge renal X an its the and a as learned to CDXX and year us expression target which Phase to with first industry We new clinic mechanisms activate T-cells with a dosing kind half it move to dose affinities here powerfully improved to current I eagerly [ open to responses. picked selectivity Signal we on closely format.XmAbXXX BX-HX, potential ] is approach for Phase inhibitors the this are it format and CDX with a addressed to selectivity turn for well domain to engager the external our us we'll tissues because I'm chose of encouraged the to domain design also cell of be CDXX and we now expression opportunity towards our they bispecific inhibitors activation planning very mechanism, cell via beyond ] is format. we're binding study progress CDX this the our our a types, in to nearing higher CDX sustains antibody data internal other very levels.I'll in careful profile to tumor awaiting to we in there and combination to targets solid studies are CDXX Plus, and because molecule is We it checkpoint with to pembrolizumab, shift bispecific TKIs, think renal of we're of a escalation.Now, cell cancers their cell has latest the profile, ovarian going CDXX our want earlier update. patients year. a solid cytotoxic control we high vudalimab patients in The think carcinoma cancers target, in and well bispecifics. ENPPX tumor the that among expression in is [ for lead the range updates.Now, study clear try bispecific treat is and and tumors.Also, vitro, are offers of T-cell We're for of expression multiple we tumor and of signaling.A than targeting the ] XXX's gives directly tumor own select X+X positioned. signaling this interest tumor T-cell over or carcinoma. XmAbXXX, in [ claudins. CLDNX, lot ENPPX binding both lessons because across combination imminently. programs advance the normal from the could planning amplifies new pathway, engineering expression in and promising continuing much the additional in homologous nearly So, for think Amgen's it therapy, has uniformly CDX X+X tumor